scholarly journals Long term use of oral contraceptives comprising synthetic estrogens induces an excessive breast cancer risk in BRCA mutation carrier women: a meta-analysis

2022 ◽  
Vol 49 (1) ◽  
pp. 1
Author(s):  
Hongling Peng ◽  
Xiaorong Qi ◽  
Qiao Wang
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Oral Contraceptives ◽  
Mutation Carrier ◽  
Brca Mutation ◽  
Meta Analysis ◽  
Brca Mutation Carrier ◽  
Synthetic Estrogens

scholarly journals Association Use of Bisphosphonates with Risk of Breast Cancer: A Meta-Analysis

2020 ◽  
Vol 2020 ◽  
pp. 1-13
Author(s):  
Rui Peng ◽  
Xingzhong Liang ◽  
Gang Zhang ◽  
Yuan Yao ◽  
Zhen Chen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Contralateral Breast Cancer ◽  
Meta Analysis ◽  
Random Effect ◽  
Random Effect Model ◽  
Contralateral Breast ◽  
Effect Model

Background. Previous studies have investigated the association between the use of bisphosphonates and the development of breast cancer, which presented controversial results. Thus, this meta-analysis was conducted to summarize the current evidence of the association of bisphosphonate use with breast cancer risk. Methods. A comprehensive search was conducted in PubMed, ISI Web of Knowledge, the Cochrane Library, and Embase from inception to March 2019 by two researches, who independently selected trials, retrieved relevant data, and assessed study quality. The summary relative risk (RR) for the use of bisphosphonates on the risks of developing breast cancer was calculated using a random-effect model. Results. The present meta-analysis, which included four case-control studies, involving 55052 breast cancer cases, and seven retrospective cohort studies, involving 14641 breast cancer cases, assessed the effect of bisphosphonates on breast cancer risk. The random-effect model meta-analysis found a reduced risk of breast cancer with exposure to bisphosphonates with pooled RR of 0.87 (95% confidence interval [CI]: 0.80 to 0.94). The short-term use of bisphosphonates (<1 year) did not render significant alteration (RR=0.92, 95% CI: 0.82 to 1.03), while a significant 26% risk reduction of breast cancer was noted with long-term use (>1 year) (RR=0.74, 95% CI: 0.62 to 0.90). A protective effect of bisphosphonates was shown in contralateral breast cancer (RR=0.41, 95% CI: 0.20 to 0.84). In terms of the type of bisphosphonates, a significant inverse relationship was noted for etidronate, with pooled RR of 0.87 (95% CI: 0.80 to 0.96). Conclusion. This meta-analysis suggested that the use of bisphosphonates was associated with reduced risk of breast cancer, including contralateral breast cancer. Compared to other types of bisphosphonates, only etidronate showed a significant inverse relationship. Additionally, the long-term use (>1 year) of bisphosphonates was more significant in lowering breast cancer risk. Further randomized controlled trials are needed to verify this association. This trial is registered with PROSPERO (registration number: CRD42018105024) (registered on 29 August 2018).

scholarly journals Association Between Antihypertensive Medication Use and Breast Cancer: A Systematic Review and Meta-Analysis

2021 ◽  
Vol 12 ◽  
Author(s):  
Yuxiu Xie ◽  
Men Wang ◽  
Peng Xu ◽  
Yujiao Deng ◽  
Yi Zheng ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Antihypertensive Medication ◽  
Meta Analysis ◽  
Cochrane Library ◽  
Breast Cancer Specific Mortality ◽  
Specific Mortality ◽  
Cancer Specific Mortality

Background: The prevalence rate of hypertension and breast cancer increases with advancing age. Renin-angiotensin system inhibitors (RASIs), β-blockers (BBs), calcium channel blockers (CCBs), and diuretics are widely used to treat patients with hypertension. Although, the association between the use of antihypertensive medication and breast cancer has been highly debated, recent evidence supporting this association remains controversial.Objective: To evaluate the association between the use of antihypertensive medication and the risk of breast cancer and its prognosis.Methods: This study was conducted using data from the PubMed, Embase, and Cochrane Library databases retrieved for the period from January 2000 to April 2021. Articles and their references were checked and summary effects were calculated using random- and fixed-effects models. Heterogeneity test and sensitivity analysis were also performed.Results: This meta-analysis included 57 articles, which were all related to breast cancer risk or prognosis. Assessment of breast cancer risk using the pooled data showed that the use of BBs or CCBs or diuretics was associated with increased cancer risk [BB: relative risk (RR) = 1.20, 95% confidence interval (CI) = 1.09–1.32; CCBs: RR = 1.06, 95% CI 1.03–1.08; diuretics: RR = 1.06, 95% CI 1.01–1.11]. Long-term use of diuretic increased the risk of breast cancer (RR = 1.10, 95% CI 1.01–1.20), whereas long-term RASIs treatment reduced the risk (RR = 0.78, 95% CI 0.68–0.91). In addition, we found that diuretic users may be related to elevated breast cancer-specific mortality [hazard ratio (HR) = 1.18, 95% CI 1.04–1.33], whereas using other antihypertensive medications was not associated with this prognosis in patients with breast cancer.Conclusion: Using CCBs, BBs, and diuretics increased the risk of breast cancer. In addition, diuretics may elevate the risk of breast cancer-specific mortality. The long-term use of RASIs was associated with a significantly lower breast cancer risk, compared with non-users. Thus, this analysis provides evidence to support the benefits of the routine use of RASIs in patients with hypertension, which has important public health implications.

scholarly journals Oral Contraceptive Used More than 5 Years is Associated with Increased Risk of Breast Cancer: A Meta-Analysis of 28,776 South East Asian Women

2019 ◽  
Author(s):  
Ricvan Dana Nindrea ◽  
Teguh Aryandono ◽  
Sumadi Lukman Anwar ◽  
Lutfan Lazuardi ◽  
Wirsma Arif Harahap ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Oral Contraceptive ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Southeast Asia ◽  
Oral Contraceptives ◽  
Meta Analysis ◽  
Reproductive Factors ◽  
Southeast Asian ◽  
Asian Women

Abstract Background: Breast cancer associated with variety of hormonal inter-ethnic and reproductive factors. Duration of oral contraceptives use with breast cancer risk is not well understood in Southeast Asian women. Methods: A comprehensive literature search of published articles from January 2001 to June 2019 (PubMed, ProQuest, and EBSCO online article databases) and meta-analysis were performed to link the duration of oral contraceptive application with risk of breast cancer among women in Southeast Asia. We identified the reference category, being ≤5 years' duration and >5 years' duration of oral contraceptive application. We use the Fixed and random-effect models to rely pooled odds ratios (OR). Egger's and Begg's test used for publication bias was presented with funnel plots. All analyzed data in Review Manager 5.3 (RevMan 5.3) and Stata version 14.2. Results: A total of 385 studies were reviewed and 10 studies involving a total of 28,776 women were included in a meta-analysis. This study found a slight increase in breast cancer risk in Southeast Asian women with oral contraceptives application ≤5 years with OR = 1.21 (95% CI 0.96-1.52, p>0.05). A higher risk of breast cancer was found in women with oral contraceptive application >5 years with OR = 2.66 (95% CI 1.79-3.94, p<0.00001). Publication bias and heterogeneity were not found particularly in a group of Southeast Asian women with oral contraceptive application for more than 5 years. Conclusion: Oral contraceptives use more than 5 years are at a higher risk in breast cancer among women in Southeast Asia. Although other reproductive factors including age at first childbirth, menarche, menopause, and lactation might influence the risk of breast cancer. Keywords: breast cancer, five years, oral contraceptive, Southeast Asia

scholarly journals Transiently increased risk of breast cancer after childbirth: implications for fertility treatments and surrogacy

2020 ◽  
Vol 35 (6) ◽  
pp. 1253-1255
Author(s):  
Zeev Blumenfeld ◽  
Norbert Gleicher ◽  
Eli Y Adashi
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Meta Analysis ◽  
Small Degree ◽  
Short Term ◽  
Benefit Ratio ◽  
Professional Societies ◽  
Fertility Treatments ◽  
Increased Risk

Abstract Whereas longstanding dogma has purported that pregnancies protect women from breast cancer, a recent meta-analysis now mandates reconsideration since it reported an actual higher breast cancer risk for more than two decades after childbirth before the relative risk turns negative. Moreover, the risk of breast cancer appears higher for women having their first birth at an older age and with a family history and it is not reduced by breastfeeding. The process of obtaining informed consent for all fertility treatments, therefore, must make patients aware of the facts that every pregnancy, to a small degree, will increase the short-term breast cancer risk. This observation may be even more relevant in cases of surrogacy where women agree to conceive without deriving benefits of offspring from assuming the risk, thus creating a substantially different risk-benefit ratio. Consequently, it appears prudent for professional societies in the field to update recommendations regarding consent information for all fertility treatments but especially for treatments involving surrogacy.

scholarly journals The Effect of Reproductive Factors on Breast Cancer Presentation in Women Who Are BRCA Mutation Carrier

2017 ◽  
Vol 20 (3) ◽  
pp. 279 ◽  
Author(s):  
Ju-Yeon Kim ◽  
Hyeong-Gon Moon ◽  
Young-Joon Kang ◽  
Wonshik Han ◽  
Woo-Chul Noh ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Mutation Carrier ◽  
Brca Mutation ◽  
Reproductive Factors ◽  
Brca Mutation Carrier

Exploring association between statin use and breast cancer risk: an updated meta-analysis

2017 ◽  
Vol 296 (6) ◽  
pp. 1043-1053 ◽  
Author(s):  
Md. Mohaimenul Islam ◽  
Hsuan-Chia Yang ◽  
Phung-Anh Nguyen ◽  
Tahmina Nasrin Poly ◽  
Chih-Wei Huang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Meta Analysis ◽  
Statin Use
Sign in / Sign up

Export Citation Format

Share Document